Total Payments
$30,434
2022 Payments
$2,783
Companies
51
Transactions
420
Medicare Patients
2,127
Medicare Billing
$205,568
Payment Breakdown by Category
Research$15,319 (50.3%)
Food & Beverage$6,932 (22.8%)
Consulting$4,190 (13.8%)
Travel$3,820 (12.6%)
Education$113.22 (0.4%)
Other$60.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,319 | 14 | 50.3% |
| Food and Beverage | $6,932 | 382 | 22.8% |
| Consulting Fee | $4,190 | 1 | 13.8% |
| Travel and Lodging | $3,820 | 18 | 12.6% |
| Education | $113.22 | 4 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60.00 | 1 | 0.2% |
Payments by Type
Research
$15,319
14 transactions
General
$15,115
406 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $16,877 | 17 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $5,833 | 13 | $0 (2021) |
| ABBVIE INC. | $1,217 | 21 | $0 (2022) |
| Novo Nordisk Inc | $799.55 | 58 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $655.32 | 22 | $0 (2021) |
| Amgen Inc. | $577.53 | 37 | $0 (2022) |
| Lilly USA, LLC | $448.62 | 33 | $0 (2021) |
| Astellas Pharma US Inc | $391.56 | 21 | $0 (2021) |
| GlaxoSmithKline, LLC. | $333.53 | 21 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $316.84 | 22 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $2,783 | 25 | Eli Lilly and Company ($2,571) |
| 2021 | $14,284 | 75 | Eli Lilly and Company ($13,031) |
| 2020 | $2,222 | 44 | Eli Lilly and Company ($1,274) |
| 2019 | $2,115 | 90 | AbbVie, Inc. ($1,013) |
| 2018 | $6,804 | 83 | Novartis Pharmaceuticals Corporation ($5,448) |
| 2017 | $2,225 | 103 | AstraZeneca Pharmaceuticals LP ($351.26) |
All Payment Transactions
420 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/02/2022 | Boston Scientific Corporation | General - Pain Management (Device) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: General - Pain Management_NMD | ||||||
| 10/28/2022 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $51.35 | General |
| 10/28/2022 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $7.06 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $487.20 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $383.96 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $259.00 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $236.70 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $230.70 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $183.20 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $183.20 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $183.20 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $180.00 | General |
| 08/30/2022 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $139.98 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $39.80 | General |
| 08/30/2022 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $5.85 | General |
| 04/06/2022 | Boston Scientific Corporation | General - Therapies (Device) | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: General - Therapies_NMD | ||||||
| 03/03/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: NEUROSCIENCE | ||||||
| 02/14/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: NEUROSCIENCE | ||||||
| 02/01/2022 | Amgen Inc. | Aimovig (Biological), Otezla, Repatha | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Neuroscience | ||||||
| 01/26/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.99 | General |
| Category: Cardiovascular | ||||||
| 01/25/2022 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Bone Health | ||||||
| 01/24/2022 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: VACCINES | ||||||
| 01/20/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: NEUROSCIENCE | ||||||
| 01/18/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: DIABETES | ||||||
| 01/17/2022 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $18.08 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $14,305 | 3 |
| M16-100 | AbbVie, Inc. | $1,013 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 30 | 30 | $8,614 | $2,691 |
| 2021 | 19 | 823 | 1,206 | $191,042 | $80,061 |
| 2020 | 26 | 1,274 | 2,850 | $331,862 | $122,816 |
Total Patients
2,127
Total Services
4,086
Medicare Billing
$205,568
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 11 | 11 | $3,465 | $1,414 | 40.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 19 | $5,149 | $1,277 | 24.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 126 | 276 | $74,796 | $35,230 | 47.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 134 | 180 | $36,180 | $14,245 | 39.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 101 | 101 | $31,815 | $12,977 | 40.8% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Office | 2021 | 101 | 101 | $17,069 | $8,201 | 48.0% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 15 | 25 | $5,625 | $1,388 | 24.7% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2021 | 52 | 52 | $3,796 | $1,363 | 35.9% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 20 | 20 | $3,660 | $1,329 | 36.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 14 | 19 | $2,584 | $1,129 | 43.7% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 58 | 58 | $2,842 | $1,048 | 36.9% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 48 | 90 | $3,690 | $873.90 | 23.7% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 17 | 21 | $3,276 | $802.74 | 24.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 25 | 25 | $1,675 | $409.71 | 24.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2021 | 14 | 14 | $938.00 | $229.04 | 24.4% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2021 | 12 | 12 | $588.00 | $216.84 | 36.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 13 | 18 | $1,206 | $198.90 | 16.5% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2021 | 27 | 27 | $189.00 | $168.21 | 89.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 12 | 129 | $645.00 | $132.93 | 20.6% |
| 81003 | Automated urinalysis test | Office | 2021 | 23 | 27 | $270.00 | $60.75 | 22.5% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2021 | 11 | 11 | $198.00 | $56.98 | 28.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 204 | 468 | $94,068 | $32,681 | 34.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 14 | 1,200 | $52,800 | $18,364 | 34.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 138 | 138 | $43,470 | $15,738 | 36.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 85 | 124 | $33,604 | $12,374 | 36.8% |
About Dr. David Jack, MD
Dr. David Jack, MD is a Obesity Medicine healthcare provider based in Draper, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255434296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Jack, MD has received a total of $30,434 in payments from pharmaceutical and medical device companies, with $2,783 received in 2022. These payments were reported across 420 transactions from 51 companies. The most common payment nature is "" ($15,319).
As a Medicare-enrolled provider, Jack has provided services to 2,127 Medicare beneficiaries, totaling 4,086 services with total Medicare billing of $205,568. Data is available for 3 years (2020–2022), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Obesity Medicine
- Location Draper, UT
- Active Since 09/06/2006
- Last Updated 02/01/2022
- Taxonomy Code 207QB0002X
- Entity Type Individual
- NPI Number 1255434296
Products in Payments
- AIMOVIG (Biological) $5,465
- Androgel (Drug) $1,042
- FARXIGA (Drug) $609.98
- Saxenda (Drug) $308.63
- Aimovig (Biological) $296.73
- JARDIANCE (Drug) $198.53
- SHINGRIX (Biological) $180.32
- VRAYLAR (Drug) $169.58
- MYRBETRIQ (Drug) $167.11
- Vascepa (Drug) $165.12
- TRULICITY (Drug) $158.33
- Victoza (Drug) $158.06
- KRYSTEXXA (Biological) $150.93
- WATCHMAN (Device) $144.32
- Tresiba (Drug) $141.76
- Tymlos (Biological) $139.75
- Ozempic (Drug) $135.69
- EMGALITY (Drug) $135.60
- XARELTO (Drug) $134.97
- SOLIQUA 100/33 (Biological) $125.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.